Efficacy Makes Sacituzumab Govitecan ‘Attractive’ in Advanced Breast Cancer

Video

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Data from the phase 3 TROPiCS-02 trial (NCT03901339) indicated that sacituzumab govitecan (Trodelvy) yielded various improvements in efficacy compared with chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

CancerNetwork® spoke with Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, ahead of the FDA’s approval of sacituzumab govitecan about data supporting the agency’s action.1

In the TROPiCS-02 trial, there was a median progression-free survival (PFS) of 5.5 months (95% CI, 4.2-7.0) in the sacituzumab arm compared with 4.0 months (95% CI, 3.1-4.4) in the chemotherapy arm (HR, 0.789; 95% CI, 0.646-0.964; P = .02).2 Additionally, the median overall survival (OS) was 14.4 months vs 11.2 months in each respective cohort (HR, 0.789; 95% CI, 0.646-0.964; P = .02).3

Tolaney noted the value of the improvements made in efficacy among patients treated with sacituzumab. “[The data] makes [sacituzumab] a really attractive agent for this patient population,” she said.

Transcript:

TROPiCS-02 had really explored sacituzumab govitecan in patients who were very heavily pretreated. They had had a prior CDK4/6 inhibitor, they had had a minimum of 2 lines of chemotherapy in the advanced disease setting, and could have received up to 4 lines of chemotherapy, so they had a median of 3 [lines of chemotherapy previously received]. [Patients were] very heavily pretreated, and patients had been randomized to get sacituzumab or to get treatment of physician's choice chemotherapy. What we saw was that sacituzumab not only improved progression-free survival but, in fact, led to statistically significant improvement in overall survival, as well as significant improvement in objective response rate. What we're seeing is that this agent does perform better than chemotherapy in this population all around in terms of response, PFS, and OS. And so I think it makes it a really attractive agent for this patient population.

References

  1. U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed February 3, 2023. https://bwnews.pr/3Y0bftX
  2. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365-3376. doi:10.1200/JCO.22.01002
  3. Rugo HS, Bardia A, Marme F, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol. 2022;33(suppl 7):S808-S869. doi:10.1016/annonc/annonc1089

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content